Free Trial

Embecta Q2 2024 Earnings Report

Embecta logo
$18.68 -0.13 (-0.69%)
As of 01/17/2025 04:00 PM Eastern

Embecta EPS Results

Actual EPS
$0.67
Consensus EPS
$0.43
Beat/Miss
Beat by +$0.24
One Year Ago EPS
$0.75

Embecta Revenue Results

Actual Revenue
$287.20 million
Expected Revenue
$264.70 million
Beat/Miss
Beat by +$22.50 million
YoY Revenue Growth
+3.60%

Embecta Announcement Details

Quarter
Q2 2024
Time
Before Market Opens

Conference Call Resources

Embecta Earnings Headlines

Embecta management to meet with BTIG
Donald Trump is about to free crypto from its chains …
With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only set to be released from its constraints … it could be about to explode. Trump has vowed to roll back Biden’s “crusade against crypto” on his first day in office.
BTIG upgrades Embecta Corporation (EMBC) to a Buy
See More Embecta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Embecta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Embecta and other key companies, straight to your email.

About Embecta

Embecta (NASDAQ:EMBC), a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

View Embecta Profile

More Earnings Resources from MarketBeat